Can a new acid blocker match the standard for stopping GI bleeding?
NCT ID NCT07776730
First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time
Summary
This trial tests whether keverprazan, a newer acid-reducing drug, is as effective as the standard drug pantoprazole at preventing rebleeding in people who have had acute non-variceal upper gastrointestinal bleeding. Adults aged 18 to 75 with confirmed non-variceal bleeding will receive either keverprazan or pantoprazole for 14 days. The main goal is to see if keverprazan is non-inferior in preventing rebleeding within that period.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Keverprazan (a potassium-competitive acid blocker) compared to pantoprazole (a proton pump inhibitor)
- What this could lead to
- If keverprazan works as well as pantoprazole, it could offer another effective option to prevent rebleeding after upper gastrointestinal bleeding.
- What could go wrong
- This is a non-inferiority trial, so it may show keverprazan is not as good. Also, results may not apply to all patients, and there are risks like rebleeding or side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 908 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria are as follows: 1. Participants presented with hematemesis, melena, or other clinical manifestations suggestive of upper gastrointestinal bleeding within 5 days before screening. 2. Participants have endoscopic confirmation of a non-variceal source of upper gastrointestinal bleeding. 3. Participants are aged between 18 and 75 years. 4. Participants who are willing to participate in this clinical trial and sign the written informed consent. Exclusion criteria are as follows: 1. Participants have experienced failure of endoscopic hemostasis, rebleeding before randomization, or a requirement for immediate transcatheter arterial embolization or surgery at the time of eligibility assessment. 2. Participants have an active malignancy or malignancy expected to interfere with survival, outcome assessment, treatment adherence, or follow-up. 3. Participants have esophageal or gastric varices or portal hypertensive gastropathy identified during endoscopic examination. 4. Participants who are unable to swallow the study medication. 5. Participants have a history of partial or total gastrectomy, gastric bypass surgery, or other major surgery. 6. Severe organ dysfunction, including any of the following: Severe hepatic or renal impairment; Unstable or severe cardiovascular, respiratory, neurological, or other systemic disease. 7. Zollinger-Ellison syndrome. 8. Any contraindication to keverprazan or pantoprazole, including known hypersensitivity to either medication or any of their components. 9. Pregnancy or lactation. 10. Participation in another clinical study within 3 months before enrollment. 11. Other situations considered by the investigator as unsuitable for enrollment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non-variceal upper gastrointestinal bleeding are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area), Shenyang, Liaoning
Shenyang, Liaoning, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.